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Abstract
Detection of acute kidney injury is undergoing a dynamic revolution of biomarker tech-
nology allowing greater, earlier, and more accurate determination of diagnosis, prognosis, 
and with powerful implication for management. Biomarkers can be broadly considered 
as any measurable biologic entity or process that allows differentiation between normal 
function and injury or disease. The ADQI (Acute Dialysis Quality Initiative) had its Ninth 
Consensus Conference dedicated to synthesis and formulation of the existing literature 
on biomarkers for the detection of acute kidney injury in a variety of settings. In the papers 
that accompany this summary, ADQI workgroups fully develop key concepts from a sum-
mary of the literature in the domains of early diagnosis, differential diagnosis, prognosis 
and management, and concurrent physiologic and imaging measures.
Copyright © 2013 S. Karger AG, Basel
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KDIGO) that AKI can be defined and graded has been a major advance in the 
phenotypic characterization as shown in figure 1 [1]. Thus the stage has been set 
for new technologies and measures to be assessed in the context of both the diag-
nosis and grading of AKI according to these standardized definitions [2].
Methods
The ADQI process was applied using previously described methodology taking advantage 
of key opinion leaders in the field and identifying appropriate topics for consensus [3]. 
The ADQI methodology comprises a systematic search for evidence with review and 
evaluation of relevant literature, establishment of clinical and physiologic outcomes for 
comparison of different treatments, description of current practice and analysis of areas 
in which evidence is lacking and a specific research agenda is required. ADQI activities 
were divided into a pre-conference, conference, and post-conference phase. Before the 
conference, topics were selected and workgroups assembled. Groups identified key ques-
tions and conducted a systematic literature search. During the conference, workgroups 
assembled in breakout sessions, as well as plenary sessions where their findings were pre-
sented, debated, and refined. Key questions were identified by the entire ADQI group, 
and the subgroups deliberated on these questions, bringing forth recommendations to the 
group as a whole. Deliberations followed three days of discussion amongst the attendees. 
Summary statements were then developed by the entire group and reported into the pres-
ent document.
Risk Stage 1
Stage 2
Stage 3
Injury
Failure
Loss
ESRD
Risk, Injury, Failure, Loss, and End-Stage Renal Disease Acute Kidney Injury Network
Cr/GFR criteria Cr criteria
Increased Cr >50%
or
GFR decreases >25%
Increased Cr >50%
or
≥0.3 mg/dl
UO <0.5 ml/kg/h
× 6 h
UO <0.5 ml/kg/h
× 12 h
UO <0.3 ml/kg/h
× 24 h
or
anuria × 12 h
Increased Cr >100%
Increased Cr >200%     
or
Cr ≥ 4 mg/dl
(with acute rise
of ≥ 0.5 mg/dl)
Increased Cr >100%
or
GFR decreases >50%
Increased Cr >200%
or
GFR decreases >75%
or
Cr ≥ 4 mg/dl
(with acute rise
of ≥ 0.5 mg/dl) 
Urine output (UO) criteria Urine output (UO) criteria
UO <0.5 ml/kg/h
× 6 h
UO <0.5 ml/kg/h
× 12 h
UO <0.3 ml/kg/h
× 24 h
or
anuria × 12 h
Persistent Acute Kidney Injury =
complete loss of renal function
for > 4 weeks
End stage renal
disease
Patients who receive renal replacement therapy
(RRT) are considered to have met the criteria for
stage 3 irrespective of the stage that they are in
at the time of commencement of RRT.
Fig. 1. The AKIN and RIFLE definitions and grading for AKI.
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Results
Early Detection of Acute Kidney Injury
The first ADQI workgroup focused on the available literature on novel blood and 
urine biomarkers that have been tested in clinical studies for the early detection of 
AKI. Recognition that cells in the kidney produce and release measurable proteins 
in the setting of a variety of injuries has been an important step in the development 
of this field [4]. Injury appears to be as subtle as volume depletion which has been 
previously termed ‘prerenal azotemia’. Data with novel markers suggest these epi-
sodes are indeed a form of AKI with some damage to cells and or complete nephron 
units [5]. More severe causes of renal damage include prolonged ischemia due to 
shock, sepsis and microcirculatory dysfunction, and direct toxicity due to injuri-
ous agents such as iodinated contrast, aminoglycosides, and vancomycin. Most of 
the markers mentioned in the accompanying article by McCullough and col-
leagues are either directly produced by renal tubular cells in response to upregula-
tion of messenger RNA and protein synthesis, or are filtered proteins that have 
reduced reabsorption by the proximal tubular cells, and hence become measurable 
in greater quantities in the urine. Since the completion of the ADQI 10 meeting, 
and important discovery that tubular cell-cycle arrest markers (insulin-like growth 
factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 
(TIMP-2)) appear to be a brief (∼36 h) harbinger to AKI that will develop in the 
next few days [6]. The concentrations of these proteins in the urine can be multi-
plied to create a value for use by clinicians to anticipate the immediate risk of AKI. 
The development of AKI from initiation of injury forward appears to be reflected 
by sharp elevation of neutrophil gelatinase-associated lipocalin (NGAL), kidney 
injury molecule-1 (KIM-1), L-type fatty acid-binding protein (L-FABP), and 
α-glutathione S-transferase (α-GST), π-GST, and interleukin-18 (IL-18). The pre-
ponderance of the data suggests these novel markers detect risk for AKI and prob-
ably actual AKI 24–48 h before the rise in serum Cr [7]. Importantly, there are 
cases where novel markers significantly elevate without a significant change in 
serum Cr or reduction in urine output, which is a late and ominous clinical devel-
opment [8]. These cases of subclinical AKI appear to have important prognostic 
implications and probably should not be dismissed (fig. 2).
Differential Diagnosis
One of the most important uses of novel biomarkers is to help evaluate a 
 patient who has a differential diagnosis in the setting of critical illness 
 including pulmonary, heart, liver, and kidney failure. The novel markers in 
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aggregate appear to have moderate specificity for AKI. Some forms of injury, 
particularly those with abnormalities in cell signaling (cytokines, adhesion 
molecules) and microvascular dysfunction, appear to favor interleukins (IL-
18), NGAL, and KIM-1 as relatively strong signals for AKI due to sepsis [9]. 
For most forms of injury, urinary levels of these markers are higher in con-
centration and have a greater rise than the same proteins measured in blood. 
When there are increases in urinary cystatin C and albumin from baseline, 
this suggests a failure in proximal renal tubular reabsorption [10]. This find-
ing is complementary to information provided by the novel biomarkers above, 
particularly in establishing AKI in the differential diagnosis of the critically ill 
patient.
Prognosis and Management
Because AKI is strongly associated with early and late mortality, even when renal 
replacement therapy is offered, biomarkers indicating AKI are prognostic for 
mortality. In general, the greater the rise in a single marker, more consistent el-
evations of more than one marker, and when in conjunction with a reduction in 
glomerular filtration and urine output, there is a quantitative relationship be-
tween the severity of AKI and clinical outcomes. Thus, as shown in figure 3, with 
more prognostic information at an earlier stage of critical illness, there can be a 
series of clinical responses leading to reduced complications and possibly im-
provement in outcomes [1]. The underlying principles have now emerged: (1) 
novel markers allow early assessment of prognosis, (2) advanced warning can 
Functional criteria and/or
RIFLE-R
or
AKIN-1
Biomarker
positivity
(+)
Biomarker
positivity
(++)
Biomarker
positivity
(+++)
RIFLE-I
or
AKIN-2
RIFLE-F
or
AKIN-3
Damage criteria
Fig. 2. Depiction of damage and functional markers in the detection of AKI. Reproduced 
with permission from ADQI [15].
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lead to changes in clinical processes, and (3) an alerted clinician and care team 
can more effectively care and communicate with patients and their families lead-
ing to improvements in delivery [11].
Physiologic and Imaging Measures
Cardiovascular medicine and oncology have taught us that the combination of 
laboratory measures and imaging/physiological assessments are powerful in 
terms of establishing internal validity, disease definitions, staging, and monitor-
ing of progression of disease. Thus, in AKI, considerable work has been under-
taken to understand core features of renal function including renal blood flow, 
regional renal perfusion, metabolism of glucose and other substrates, and the net 
control over renal filtration and urine output. A current standard of care in a 
case of de novo AKI includes renal ultrasonography which primarily establishes 
the presence of polycystic kidney disease, ureteral disease and obstruction, and 
helps somewhat to establish or support baseline chronic kidney disease with 
measurement of renal size. Ultrasound, however, is not helpful in diagnosing 
AKI in patient with normal size kidneys and no obstruction to urinary flow. The 
most promising novel approaches include renal time assessment of renal blood 
flow, oxygenation, and glomerular filtration [12, 13]. It is possible that discovery 
Actions
recommended
to start when
patients are
at high risk...
KDIGO consensus guideline for AKI
AKI stage
Stage 1 Stage 2 Stage 3
Discontinue all nephrotoxic agents when possible
Ensure volume status and perfusion pressure
Non-invasive diagnostic workup
Check for changes in drug dosing
Avoid subclavian catheters if possible
Consider ICU admission
Consider renal replacement therapy
Consider invasive diagnostic workup
Consider alternatives to radiocontrast procedures
Avoid hyperglycemia
Monitor serum creatinine and urine output
Consider functional hemodynamic monitoring
High risk
Fig. 3. Recognition of AKI and clinical responses. Adapted from KDIGO [1].
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of a drop in renal filtration could occur many hours/days before serum Cr ele-
vates, and thus give useful information to the clinician following the manage-
ment principles discussed above [14].
Conclusions
AKI is a dynamic process that generates a multitude of biologic signals that when 
measured, become clinical biomarkers. Use of these markers appears to be valu-
able in the detection, differential diagnosis, prognosis, and management of pa-
tients in the setting of critical illness. Future research focused on the develop-
ment and use of new diagnostic and therapeutic targets is critical to advance the 
field of critical care nephrology.
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